# Healthgen Biotech

its OsrHSA injection (奥福民®) became the world's first NMPA-approved rHSA therapeutic injection in July 2025 — also the first globally-approved rice-derived recombinant protein drug — backed by a multicentre, randomised, double-blind,…

Source: https://en.bioecon.ru/companies/healthgen-biotech/
Updated: 2026-08-15

- Country: China
- Ticker: SSE:688765

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | raised approximately RMB 2.6 billion (approx. $366 million) in an October 2025 IPO on the Shanghai Stock Exchange STAR Market | http://biobase.whitefordresearch.com/companies/healthgen-biotechnology, https://www.dehenglaw.com/EN/newscontent/0006/035237/2.aspx?MID=0876 |
| Funding | secured RMB 556.3155 million (approx. $87.6 million) in a Pre-IPO financing round in February/March 2022 | http://biobase.whitefordresearch.com/companies/healthgen-biotechnology |
| Capacity | 10 tons of HSA stock solution annually, with a total capacity planned to rise to 130 tons in 2026 | https://english.wuhan.gov.cn/H_1/NWP/202507/t20250720_2622306.shtml, https://www.chinadaily.com.cn/a/202507/18/WS687a4926a310ad07b5d90c2b.html |
| Capacity | 1 million doses of formulations annually, with plans to increase to 12 million doses | https://regional.chinadaily.com.cn/eastlakehightechzone/2024-03/15/c_971374.htm |
| Certification | obtained a drug manufacturing certificate from the Hubei medical products administration | https://regional.chinadaily.com.cn/eastlakehightechzone/2024-03/15/c_971374.htm, https://static.cninfo.com.cn/finalpage/2025-09-23/1224675477.PDF |
| Regulatory approval | received NMPA approval for its rice-derived recombinant human albumin injection (OsrHSA/HY1001) in July 2025 | https://cen.acs.org/pharmaceuticals/biologics/Albumin-made-rice-game-changing/103/web/2025/10, https://static.cninfo.com.cn/finalpage/2025-09-23/1224675477.PDF, https://www.chinadaily.com.cn/a/202507/18/WS687a4926a310ad07b5d90c2b.html |
| Production site | headquartered in the East Lake High-Tech Development Zone, Wuhan, China, with production facilities including a cGMP-compliant smart manufacturing base | https://static.cninfo.com.cn/finalpage/2025-09-23/1224675477.PDF |

Independent sources: biobase.whitefordresearch.com, cen.acs.org, chinadaily.com.cn, dehenglaw.com, english.wuhan.gov.cn, regional.chinadaily.com.cn, static.cninfo.com.cn

## Technologies

- [Recombinant human serum albumin (rHSA)](https://en.bioecon.ru/technology/recombinant-human-serum-albumin/)